CRBP – Corbus Pharmaceuticals Holdings, Inc.
Float Short %
8.27
Margin Of Safety %
Put/Call OI Ratio
0.06
EPS Next Q Diff
0.44
EPS Last/This Y
-3.02
EPS This/Next Y
1.49
Price
8.69
Target Price
42.05
Analyst Recom
1
Performance Q
-50.79
Relative Volume
0.25
Beta
2.87
Ticker: CRBP
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | CRBP | 8.32 | 0.09 | 2.00 | 1988 |
| 2025-12-29 | CRBP | 8.23 | 0.09 | 2.14 | 1975 |
| 2025-12-30 | CRBP | 8.05 | 0.10 | 0.00 | 2013 |
| 2025-12-31 | CRBP | 8.13 | 0.09 | 0.00 | 1989 |
| 2026-01-02 | CRBP | 7.89 | 0.09 | 0.00 | 1991 |
| 2026-01-05 | CRBP | 7.82 | 0.09 | 0.04 | 1995 |
| 2026-01-06 | CRBP | 8.06 | 0.09 | 0.00 | 2005 |
| 2026-01-07 | CRBP | 8.42 | 0.09 | 0.00 | 2006 |
| 2026-01-08 | CRBP | 8.36 | 0.09 | 0.00 | 2027 |
| 2026-01-09 | CRBP | 8.35 | 0.09 | 0.00 | 2027 |
| 2026-01-12 | CRBP | 7.99 | 0.08 | 1.18 | 2222 |
| 2026-01-13 | CRBP | 7.94 | 0.08 | 0.40 | 2211 |
| 2026-01-14 | CRBP | 8.27 | 0.08 | 1.00 | 2215 |
| 2026-01-15 | CRBP | 8.18 | 0.08 | 0.02 | 2217 |
| 2026-01-16 | CRBP | 8.34 | 0.08 | 0.00 | 2337 |
| 2026-01-20 | CRBP | 8.6 | 0.11 | 0.00 | 1737 |
| 2026-01-21 | CRBP | 8.68 | 0.09 | 0.00 | 2134 |
| 2026-01-22 | CRBP | 8.85 | 0.07 | 0.00 | 2717 |
| 2026-01-23 | CRBP | 8.72 | 0.06 | 0.01 | 2756 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | CRBP | 8.31 | -104.5 | -30.1 | -6.71 |
| 2025-12-29 | CRBP | 8.20 | -104.5 | -31.0 | -6.71 |
| 2025-12-30 | CRBP | 8.02 | -104.5 | -26.9 | -6.71 |
| 2025-12-31 | CRBP | 8.12 | -104.5 | -40.8 | -6.71 |
| 2026-01-02 | CRBP | 7.86 | -104.5 | -22.5 | -6.71 |
| 2026-01-05 | CRBP | 7.81 | -104.5 | -33.9 | -6.71 |
| 2026-01-06 | CRBP | 8.06 | -104.5 | -47.3 | -6.71 |
| 2026-01-07 | CRBP | 8.43 | -104.5 | -53.3 | -6.71 |
| 2026-01-08 | CRBP | 8.37 | -104.5 | -33.0 | -6.71 |
| 2026-01-09 | CRBP | 8.31 | -104.5 | -33.2 | -6.71 |
| 2026-01-12 | CRBP | 7.99 | -104.5 | -21.8 | -6.71 |
| 2026-01-13 | CRBP | 7.96 | -104.5 | -35.0 | -6.71 |
| 2026-01-14 | CRBP | 8.26 | -104.5 | -51.4 | -6.71 |
| 2026-01-15 | CRBP | 8.20 | -104.5 | -32.0 | -6.71 |
| 2026-01-16 | CRBP | 8.32 | -104.5 | -42.4 | -6.71 |
| 2026-01-20 | CRBP | 8.60 | -104.5 | -48.0 | -6.71 |
| 2026-01-21 | CRBP | 8.67 | -104.5 | -37.1 | -6.71 |
| 2026-01-22 | CRBP | 8.88 | -104.5 | -44.2 | -6.71 |
| 2026-01-23 | CRBP | 8.69 | -104.5 | -28.8 | -6.71 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | CRBP | -4.73 | -1.18 | 8.00 |
| 2025-12-29 | CRBP | -4.73 | -1.18 | 8.00 |
| 2025-12-30 | CRBP | -4.73 | -1.18 | 8.00 |
| 2025-12-31 | CRBP | -4.73 | -1.18 | 8.00 |
| 2026-01-02 | CRBP | -4.73 | -1.18 | 8.00 |
| 2026-01-05 | CRBP | -4.75 | -1.16 | 8.00 |
| 2026-01-06 | CRBP | -4.75 | -1.16 | 8.00 |
| 2026-01-07 | CRBP | -4.75 | -1.16 | 8.00 |
| 2026-01-08 | CRBP | -4.75 | -1.16 | 8.00 |
| 2026-01-09 | CRBP | -4.75 | -1.16 | 8.00 |
| 2026-01-12 | CRBP | -4.72 | -1.16 | 8.00 |
| 2026-01-13 | CRBP | -4.75 | -1.16 | 8.16 |
| 2026-01-14 | CRBP | -4.75 | -1.16 | 8.16 |
| 2026-01-15 | CRBP | -4.75 | -1.16 | 8.16 |
| 2026-01-16 | CRBP | -4.75 | -1.16 | 8.16 |
| 2026-01-20 | CRBP | -4.75 | -1.01 | 8.16 |
| 2026-01-21 | CRBP | -4.75 | -1.01 | 8.16 |
| 2026-01-22 | CRBP | -4.75 | -1.01 | 8.27 |
| 2026-01-23 | CRBP | -4.14 | -1.01 | 8.27 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.9
Avg. EPS Est. Current Quarter
-1.59
Avg. EPS Est. Next Quarter
-1.46
Insider Transactions
-4.14
Institutional Transactions
-1.01
Beta
2.87
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
Fair Value
Quality Score
6
Growth Score
22
Sentiment Score
59
Actual DrawDown %
92.8
Max Drawdown 5-Year %
-97.9
Target Price
42.05
P/E
Forward P/E
PEG
P/S
P/B
1.19
P/Free Cash Flow
EPS
-5.51
Average EPS Est. Cur. Y
-6.71
EPS Next Y. (Est.)
-5.21
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.25
Return on Equity vs Sector %
-100.5
Return on Equity vs Industry %
-84.5
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.32
EBIT Estimation
-28.8
Corbus Pharmaceuticals HoldingsSector: Healthcare
Industry: Biotechnology
Employees: 28
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
stock quote shares CRBP – Corbus Pharmaceuticals Holdings, Inc. Stock Price stock today
news today CRBP – Corbus Pharmaceuticals Holdings, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CRBP – Corbus Pharmaceuticals Holdings, Inc. yahoo finance google finance
stock history CRBP – Corbus Pharmaceuticals Holdings, Inc. invest stock market
stock prices CRBP premarket after hours
ticker CRBP fair value insiders trading